China Resources Boya Bio-pharmaceutical Group Co.,Ltd

XSEC:300294 Stock Report

Market Cap: CN¥15.6b

China Resources Boya Bio-pharmaceutical GroupLtd Balance Sheet Health

Financial Health criteria checks 6/6

China Resources Boya Bio-pharmaceutical GroupLtd has a total shareholder equity of CN¥7.6B and total debt of CN¥2.1M, which brings its debt-to-equity ratio to 0.03%. Its total assets and total liabilities are CN¥8.2B and CN¥576.0M respectively. China Resources Boya Bio-pharmaceutical GroupLtd's EBIT is CN¥485.6M making its interest coverage ratio -42.1. It has cash and short-term investments of CN¥5.2B.

Key information

0.03%

Debt to equity ratio

CN¥2.09m

Debt

Interest coverage ratio-42.1x
CashCN¥5.24b
EquityCN¥7.58b
Total liabilitiesCN¥575.96m
Total assetsCN¥8.16b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 300294's short term assets (CN¥6.6B) exceed its short term liabilities (CN¥548.6M).

Long Term Liabilities: 300294's short term assets (CN¥6.6B) exceed its long term liabilities (CN¥27.4M).


Debt to Equity History and Analysis

Debt Level: 300294 has more cash than its total debt.

Reducing Debt: 300294's debt to equity ratio has reduced from 14.6% to 0.03% over the past 5 years.

Debt Coverage: 300294's debt is well covered by operating cash flow (18134.3%).

Interest Coverage: 300294 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 01:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China Resources Boya Bio-pharmaceutical Group Co.,Ltd is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Fang QuanChina International Capital Corporation Limited
Bing ZhaoChina Renaissance Securities